HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by CLAXTON, A. J. Articles by McKENDRICK, J. Search for Related Content PubMed PubMed Citation Articles by CLAXTON, A. J. Articles by McKENDRICK, J.

Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression

Global Health Outcomes Research, Eli Lilly and Company, Indianapolis, IN and Indiana University School of Medicine, Department of Public Health, Indianapolis, IN

ZHIMING LI, PhD

Pharmacia & Upjohn, Kalamazoo, MI

JAN McKENDRICK, MSc

Health Outcomes, Eli Lilly and Company Limited, Basingstoke, UK

Correspondence: Dr Ami J. Claxton, Global Health Outcomes Research, Eli Lilly and Company, Indianapolis, IN 46285, USA. Tel: 317-277-3494; Fax: 317-276-6026; e-mail: ami.claxton{at}lilly.com

Declaration of interest Funding provided by Eli Lilly and Company.

Background Patients with depression are often not prescribed antidepressants for an adequate period of time.

Aims The impact of antidepressant prescribing patterns on the risk of relapse or recurrence of depression is examined.

Method The Medi Plus UK Primary Care Database was used to identify patients treated for depression with a selective serotonin reuptake inhibitor (SSRI). Records were used to construct hierarchical prescription patterns (less than 120 days, switching/augmentation, upward titration, or stable use) as indicators for the occurrence of relapse or recurrence of depression.

Results Patients with stable use experienced the lowest risk of relapse or recurrence. Factors significantly associated with increased risk include prior use of anxiolytic medications, more comorbid conditions and younger age.

Conclusions The SSRI prescription pattern most consistent with recommended depression treatment guidelines was associated with the lowest risk of relapse or recurrence.

This article has been cited by other articles:

				M Brandt-Christensen, K Kvist, F M Nilsson, P K Andersen, and L V Kessing Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 781 - 783. [Abstract] [Full Text] [PDF]

				D. G. Hansen, W. Vach, J.-U. Rosholm, J. Sondergaard, L. F Gram, and J. Kragstrup Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics Fam. Pract., December 1, 2004; 21(6): 623 - 629. [Abstract] [Full Text] [PDF]

				I. M. Anderson and J. G. Edwards Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness Advan. Psychiatr. Treat., May 1, 2001; 7(3): 170 - 180. [Full Text]